Press release – For immediate release – 5:45 pm CEST
Half year Median Technologies liquidity contract statement
Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “the Company”) to TP ICAP (Europe), the following resources were listed in the liquidity account as of June 28, 2024:
- 36,135 shares
- €89,040.54 in cash
Transactions during the first half 2024:
| BUY | 183,582 shares | 596,810.69 EUR | 418 transactions |
| SELL | 175,675 shares | 580,167.80 EUR | 384 transactions |
For information, as of December 29th, 2023, the following resources were listed in the liquidity contract:
- 28,228 shares
- €106,617.89 in cash
For information, as of May 4th, 2020, when the new liquidity contract was set up, the following resources were listed in the liquidity account:
- 4,404 shares
- €173,829.64 in cash
The daily transaction table is provided in the appendix to this press release. TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel (ACPR) and the Autorité des Marchés Financiers (AMF).
Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit